This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
St. Luke's-Roosevelt Hospital Center
ClinicalTrials.gov Identifier:
NCT01837680
First received: April 4, 2013
Last updated: May 24, 2017
Last verified: May 2017
  Purpose
The aim of this study is to compare glycemic control in pregnant women treated with insulin Detemir and pregnant women treated with NPH insulin. These women are diagnosed with gestational diabetes (GDM) in the current pregnancy or have a preexisting diagnosis of type 2 diabetes (T2DM) at the onset of pregnancy. Our hypothesis is that there is no difference between these two treatment modalities in terms of glycemic control in diabetes.

Condition Intervention
Diabetes, Gestational Diabetes, Type 2 Drug: Insulin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Insulin Detemir Versus Insulin NPH: A Randomized Prospective Study Comparing Glycemic Control in Pregnant Women With Diabetes

Resource links provided by NLM:


Further study details as provided by St. Luke's-Roosevelt Hospital Center:

Primary Outcome Measures:
  • Glycemic Control [ Time Frame: up to 41 weeks ]
    Overall mean glucose value of pregnancy. This will be determined by the sum of average glucose value at each visit, divided by the number of visits.


Secondary Outcome Measures:
  • Number of Patients Obtaining Glycemic Control [ Time Frame: up to 41 weeks ]
    Number of each group that obtains glycemic control, defined as mean glucose <100mg/dl.

  • Time to Achieve Glycemic Control [ Time Frame: up to 41 weeks ]
    Time (weeks) to achieve glycemic control, as defined as mean glucose <100mg/dl

  • Average Fasting Glucose [ Time Frame: up to 41 weeks ]
    Mean fasting blood glucose in pregnancy, as determined by the sum of the mean fasting glucose at each visit divided by the number of visits

  • Post-prandial Blood Glucose [ Time Frame: up to 41 weeks ]
    Mean post-prandial blood glucose in pregnancy, as defined as the sum of the average post-prandial blood glucose at each visit divided by the number of visits.

  • Weight Gain [ Time Frame: Number of pounds gained at each visit up to 41 weeks ]
    Total weight gain in pregnancy

  • Neonatal Weight [ Time Frame: At delivery, up to 41 weeks ]
    Neonatal weight was estimated for occurrence of neonatal macrosomia (≥4000g birth weight) and neonatal LGA(large for gestational age)(birth weight >90th percentile for gestational age

  • Gestational Age at Delivery [ Time Frame: at delivery, up to 41 weeks ]
    Gestational age at delivery

  • Maternal Hypoglycemia [ Time Frame: at delivery, up to 41 weeks ]
    Number of participants with incidence of maternal hypoglycemia (<60mg/dl)

  • Neonatal Bilirubin [ Time Frame: at birth, up to 41 weeks ]
    Percentage of neonatal hyperbilirubinemia - data not collected

  • Intensive Care Admissions [ Time Frame: at birth, up to 41 weeks ]
    Number of participants with incidence of neonatal intensive care unit admissions

  • Delivery Mode [ Time Frame: at birth, up to 41 weeks ]
    method of delivery including cesarean section, vaginal delivery, or assisted vaginal delivery - data not collected

  • Birth Rate [ Time Frame: at birth, up to 41 weeks ]
    Number of live birth rate

  • Shoulder Dystocia [ Time Frame: at birth, up to 41 weeks ]
    Incidence of shoulder dystocia - data not collected

  • Polyhydramnios [ Time Frame: at each visit in pregnancy up to 41 weeks ]
    Incidence of polyhydramnios (defined as amniotic fluid index (AFI)>20 or deepest vertical pocket ≥8) - data not collected

  • Neonatal Hypoglycemia [ Time Frame: at birth, up to 41 weeks ]
    Number of participants with incidence of blood sugar <40mg/dl in neonate


Enrollment: 105
Study Start Date: March 2013
Study Completion Date: March 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Levemir
Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will take half of the short-acting dose with breakfast and the other half with lunch. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
Drug: Insulin
Other Names:
  • Insulin NPH
  • Insulin Levemir
Active Comparator: NPH
Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will get the entire dose of short-acting insulin with breakfast. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
Drug: Insulin
Other Names:
  • Insulin NPH
  • Insulin Levemir

Detailed Description:
The experimental method will be a randomized controlled trial performed at Roosevelt Hospital in our Diabetes in Pregnancy Program (DIPP). Perinatologists managing the patient in DIPP determine when patients need further treatment with medical therapy. Patients undergoing care at DIPP may require medical intervention in the following clinical scenarios: failure of diet alone to control glycemic indices and grossly abnormal glucose tolerance screening test results suggesting disease of such severity that diet alone would not be sufficient. After verbally counseling the patient, she will be recruited for the study by the investigators. An extensive explanation of the objectives of the study will be presented to the patient, as well as written copies of the protocol and consent. After informed consent is given, patients will be randomized to management with either insulin NPH or detemir together with rapid acting insulin aspart (Novolog) with meals, as necessary. The primary outcome will be level of glycemic control defined as overall mean blood glucose in pregnancy. This is a well established measure of overall glycemic control that has been used in numerous publications in the obstetric literature on diabetes in pregnancy. Participants will be followed until they deliver, with an expected range of 6-16 weeks depending on when the patient was enrolled in the study. The mean glucose will be determined by the sum of average glucose at each visit divided by the number of visits).
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • All pregnant women with a viable singleton or multiple gestation at ≤34 weeks with gestational diabetes diagnosed in their current pregnancy requiring medical therapy. "Early diagnosis" GDM patients will also be included; which is defined as a diagnosis made prior to 24 weeks.
  • Women with known preexisting type 2 diabetes that are in need of medical therapy.

Exclusion criteria:

  • Patients <18 years of age
  • a diagnosis of GDM outside of the gestational age stated above
  • known allergy/prior adverse reaction to insulin NPH or insulin detemir.
  • type 1 diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01837680

Locations
United States, New York
St. Luke's-Roosevelt Hospital Center
New York, New York, United States, 10019
Sponsors and Collaborators
St. Luke's-Roosevelt Hospital Center
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: St. Luke's-Roosevelt Hospital Center
ClinicalTrials.gov Identifier: NCT01837680     History of Changes
Other Study ID Numbers: 12-166
Study First Received: April 4, 2013
Results First Received: January 12, 2017
Last Updated: May 24, 2017

Keywords provided by St. Luke's-Roosevelt Hospital Center:
Insulin, Long-Acting

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes, Gestational
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pregnancy Complications
Insulin, Globin Zinc
Isophane insulin, beef
Insulin
Insulin Detemir
Isophane Insulin, Human
Insulin, Isophane
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 18, 2017